Key facts
- It has raised $1.1M; the latest was Early Stage VC ($1.1M) in May 2025.
- Notable investors include CoInvest Capital, Superhero Capital, Sofigama Investments, NGL Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for VUGENE
- ·The full record, as it builds
Funding rounds
No funding rounds for VUGENE are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About VUGENE
Developer of a multi-omics platform designed to boost productivity by transforming the discovery process. The company helps to study omics data and offers data science collaborators, bioinformatics research and expert guidance, enabling research institutions, biotech companies, hospitals and pharmaceutical companies to help solve research problems.
- Sector
- Information Technology
- HQ
- Kaunas, Lithuania
- Founded
- 2021
- Employees
- 10
- Website
- vugene.com/
- Ownership
- Privately Held (backing)
VUGENE doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in VUGENE shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on VUGENE in its N-PORT filings yet. We sweep new filings monthly.